Progress in cancer research reveals promising therapeutic and diagnostic breakthroughs. Advancements in antibody-drug conjugates (ADCs) demonstrate enhanced selectivity and clinical potential against hematologic and solid tumors. Shape Therapeutics and VectorY signed a $1.2 billion deal to advance brain-penetrating AAV capsids for neurodegenerative disease gene therapies. Luxa Biotechnology reported Phase 1/2a positive results with RPE stem cell therapy for dry age-related macular degeneration, offering hope for vision restoration. Cutting-edge urine-based cancer diagnostics and multiomic proteogenomic approaches are refining early detection and individualized treatment strategies across multiple cancers.